The short version: the ROI case for precision medicine has shifted from "Does it work?" to "Where does it work, and how do you operationalize it?" Most health systems that expected broad, enterprise-wide financial returns have been disappointed. Systems that focused on a handful of high-value clinical use cases have generally seen better clinical outcomes and more sustainable economics.
Here's how many health system executives are now thinking about it.
| Dimension | Reality today |
|---|
| Clinical value | Strong in selected diseases (oncology, rare disease, pharmacogenomics, inherited cardiovascular conditions) |
| Enterprise ROI | Usually modest or delayed |
| Department-level ROI | Often positive in targeted programs |
| Strategic value | Increasingly important for research, referrals, and specialty growth |
| Time to measurable ROI | Typically 3–7 years rather than 12–24 months |
Where the ROI is actually being realized
The biggest lesson from the last decade is that genomics is not one product.
Different use cases have completely different economics.
1. Oncology (highest maturity)
This remains the strongest business case.
Value comes from:
- avoiding ineffective therapies
- matching patients to targeted drugs
- increasing clinical trial enrollment
- reducing unnecessary treatment
- attracting tertiary referrals
Financial benefits often include:
- higher specialty service revenue
- improved quality metrics
- increased research funding
- better payer negotiations for evidence-based testing
This is why virtually every major academic medical center began here.
2. Rare disease diagnosis
The ROI is less about revenue and more about avoiding years of expensive diagnostic workups.
Benefits include:
- fewer unnecessary admissions
- fewer repeat imaging studies
- fewer specialist consultations
- earlier treatment
Health economists often describe this as avoiding the "diagnostic odyssey."
3. Pharmacogenomics
This is becoming one of the more attractive implementation opportunities.
Examples include medications such as:
- antidepressants
- anticoagulants
- certain pain medications
- oncology drugs
Potential value:
- fewer adverse drug events
- lower readmissions
- shorter time to effective therapy
The challenge is embedding genomic results into prescribing workflows so clinicians actually use them.
4. Population genomics
This has the weakest near-term ROI.
Large-scale genomic screening programs are valuable from a public health perspective but require:
- longitudinal follow-up
- extensive genetic counseling
- sophisticated data infrastructure
Financial returns are difficult for individual health systems because many benefits accrue years later and may be realized by another payer.
Why many programs struggled financially
Health systems initially underestimated several implementation costs.
Major cost drivers include:
- sequencing
- bioinformatics infrastructure
- variant interpretation
- genetic counselors
- EHR integration
- clinician education
- governance
- ongoing data maintenance
The sequencing itself is no longer the dominant expense.
Today, workflow and implementation account for much of the total cost.
What successful health systems do differently
Recent implementation research suggests more mature programs share several characteristics.
Phase 1: Focus on 2–4 high-value use cases
Rather than launching "precision medicine" broadly, they prioritize areas with established evidence, such as:
- molecular oncology
- pharmacogenomics
- rare disease diagnostics
- hereditary cancer screening
Phase 2: Build the data layer
Critical capabilities include:
- genomic data repository
- standards-based interoperability
- clinical decision support
- integration with the EHR
- consent management
Without these, genomic results often become PDFs that clinicians rarely revisit.
Phase 3: Build clinical workflows
Successful programs invest in:
- referral pathways
- genetic counseling
- multidisciplinary review boards
- ordering guidance
- clinical education
Technology alone does not change practice.
Phase 4: Generate real-world evidence
Leading organizations increasingly measure:
- avoided hospitalizations
- medication changes
- survival
- quality outcomes
- downstream costs
- patient-reported outcomes
This evidence supports payer discussions and program expansion.
Where AI changes the equation
AI is becoming a force multiplier rather than a replacement for genomics.
Health systems are applying AI to:
- variant interpretation
- clinical documentation
- phenotype extraction from EHRs
- patient identification
- trial matching
- risk prediction
The economic impact is less about replacing clinicians and more about reducing manual interpretation and improving scalability.
What boards and CFOs increasingly want to see
Instead of asking, "What's the ROI of precision medicine?" they ask:
- Which service lines improve margin?
- Which quality metrics improve?
- Which admissions are avoided?
- Which specialty referrals increase?
- Which research dollars become available?
- Which payer contracts improve?
- How much clinician time is saved?
That reflects a shift from treating precision medicine as a standalone investment to viewing it as infrastructure that supports multiple strategic objectives.
A pragmatic roadmap (2026–2030)
A realistic roadmap for an integrated delivery network might look like:
- Launch evidence-backed programs in oncology, pharmacogenomics, and rare disease diagnostics.
- Embed genomic results directly into EHR-based clinical decision support.
- Establish governance for data quality, privacy, consent, and equity.
- Track both clinical outcomes and financial metrics from the outset.
- Expand into preventive and population genomics only after demonstrating value in targeted programs.
This staged approach aligns with recent health system implementation studies and broader international guidance emphasizing infrastructure, governance, workforce development, and equitable integration rather than enterprise-wide rollout from day one.
The overall picture is that precision medicine is increasingly seen as a strategic capability rather than a quick-return investment. Health systems that concentrate on high-value clinical applications, integrate genomics into routine workflows, and build evidence iteratively are reporting more sustainable results than those that attempted broad genomic programs without clear operational priorities.
